GlassScriptPhysician profile
Sarah F Daniel
NPI 1750464541
$6,225.72
in general payments reported to CMS, 2019-2025
47 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $2,905 · 2023: $2,104 · 2024: $373 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412 · Consulting Fee: $250 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.74 |
| Consulting Fee | $250.00 |
| Education | $195.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $1,323.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $499.43 | 2021-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $309.17 | 2021-2023 | Darzalex, Tecvayli, Imbruvica |
| Glaxosmithkline, LLC. | $271.73 | 2022-2023 | Zejula |
| Novartis Pharmaceuticals Corporation | $256.72 | 2021-2024 | |
| Genzyme Corporation | $228.65 | 2021-2023 | |
| Genentech, INC. | $225.81 | 2023-2024 | Columvi, Polivy, Itovebi |
| Seagen INC. | $221.82 | 2021-2023 | Tivdak, Tukysa, Padcev |
| Daiichi Sankyo INC. | $213.16 | 2021-2023 | Enhertu, Injectafer |
| Incyte Corporation | $212.18 | 2021-2024 | Jakafi, Monjuvi |
| Celgene Corporation | $195.79 | 2022-2023 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $174.82 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Kite Pharma, INC. | $164.11 | 2022-2023 | |
| Exelixis INC. | $131.99 | 2021-2023 | Cabometyx |
| Gilead Sciences, INC. | $127.94 | 2022-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $122.41 | 2021-2023 | Lunsumio, Venclexta |
| Aveo Pharmaceuticals, INC. | $121.33 | 2022-2023 | Fotivda |
| Organon LLC | $115.28 | 2022-2025 | Ontruzant, Renflexis |
| Abbott Laboratories | $113.74 | 2024-2025 | Triclip |
| Pfizer INC. | $102.56 | 2022-2023 | |
| Emd Serono, INC. | $90.93 | 2022-2023 | Bavencio |
| Foundation Medicine, INC. | $90.75 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $79.22 | 2022-2023 | Opdualag |
| Janssen Scientific Affairs, LLC | $76.25 | 2025 | Carvykti, Tecvayli |
| Eisai INC. | $71.64 | 2022-2023 | |
| Blueprint Medicines Corporation | $50.48 | 2021-2023 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $49.02 | 2022-2023 | Monoferric |
| Lilly USA, LLC | $47.03 | 2021 | |
| Eusa Pharma (US) LLC | $45.34 | 2022 | |
| Rigel Pharmaceuticals, INC. | $43.49 | 2022-2023 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $40.07 | 2022-2023 | |
| Kyowa Kirin, INC. | $40.00 | 2022 | |
| Taiho Oncology, INC. | $39.29 | 2021-2022 | |
| Array Biopharma INC | $39.11 | 2022-2023 | Xalkori, Lorbrena, Braftovi |
| Sobi, INC | $31.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.69 | 2023 | |
| Jazz Pharmaceuticals INC. | $29.08 | 2021 | |
| Genmab U.S., INC. | $28.88 | 2023 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $28.11 | 2023 | Imbruvica |
| Abbvie INC. | $22.74 | 2022 | |
| Mirati Therapeutics, INC. | $19.27 | 2023 | Krazati |
| Agios Pharmaceuticals, INC. | $19.12 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.70 | 2023 | Qinlock |
| Tersera Therapeutics LLC | $18.26 | 2023 | Zoladex |
| Servier Pharmaceuticals LLC | $17.78 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.38 | 2023 | Oxlumo |
| Clovis Oncology, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.